Cryptome to collaborate with IMB

By Melissa Trudinger
Tuesday, 07 December, 2004

Cryptome (ASX: CRP) has signed a memorandum of understanding with the Institute of Molecular Bioscience (IMB) to collaborate on the identification of cardiovascular therapeutics.

The company will combine the high throughput screening capabilities of Cryptomics platform technology, which is based on the identification of small protein fragments with previously undiscovered therapeutic activity, with the IMB's compound libraries, to identify compounds with therapeutic potential in the treatment of cardiovascular disease.

"Bringing together IMB's novel compound libraries and our screening capabilities will make a powerful combination in a most important clinical area," said Cryptome's acting CEO Prof Mathew Vadas.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd